Research and Markets: Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023: Anti-Factor D (Also Known as RG7417 by Roche and as FCFD4514S by Its Subsidiary, Genentech)

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/c33bx7/lampalizumab) has announced the addition of the "Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.

Lampalizumab, also known as anti-factor D (as well as RG7417 by Roche and as FCFD4514S by its subsidiary, Genentech), is an antigen-binding fragment of a humanized mAb that targets complement factor D, the rate-limiting enzyme involved in the activation of the alternative complement pathway.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Lampalizumab including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Lampalizumab for the top country from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Macular Degeneration Overview

3.2 Macular Edema Overview

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Macular Edema Diagnosis

4.1.2 Macular Degeneration Diagnosis

4.1.3 Treatment Guidelines and Leading Prescribed Drugs

4.1.4 Clinical Practice

5 Competitive Assessment

6 Unmet Need and Opportunity

6.1 Overview

6.2 Treatment for Dry AMD

6.3 Longer-Acting Anti-VEGF Drug Therapy

6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD

6.5 Less Invasive Drug Formulations

6.6 Awareness and Earlier Patient Diagnosis

6.7 Home Monitoring of AMD Progression

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

8 Lampalizumab

9 Appendix

For more information visit http://www.researchandmarkets.com/research/c33bx7/lampalizumab

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals